Opsens – 50,000 patients diagnosed with the OptoWire

November 1, 2018 / Portfolio News

QUEBEC CITY, Nov. 1, 2018 /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) has reached an important milestone with more than 50,000 patients assessed with the OptoWire™, a pressure guidewire used to measure Fractional Flow Reserve (“FFR”) to diagnose and treat cardio vascular disease.

The use of pressure guidewires to measure FFR for the evaluation of coronary blockages has grown over the years and is now considered the gold standard. Clinical data have shown a reduction in mortality in patients assessed using this technique.

As Societies of Cardiology are recommending expanding the use of pressure guidewires and physiology assessments, Opsens has scaled up manufacturing to respond to the growing demand for the OptoWire in its main markets, namely Japan, the United States, Europe and Canada, and to expand its reach to new geographies.

“This milestone is a testament to the quality of our product, of our team and of our vision to take on the challenge to bring a second-generation fiber optic technology pressure guidewire to the market,” said Louis Laflamme, President and CEO. “Our customers are delighted by the benefits brought on by the OptoWire and we are encouraged by their excellent feedback in terms of diagnostic accuracy as well as the time-saving and cost-effectiveness it can provide to the procedure.”

Opsens differentiates from the competition by the performance of the OptoWire in terms of vessel accessibility, as well as for the reliability and the accuracy of its second-generation fiber optic sensor.

Market adoption of the OptoWire has grown at a rapid pace and Opsens is now commercializing the OptoWire in more than 30 countries, with especially robust growth in the United States and Japan.

Laflamme concluded by sharing the unique passion that lives at Opsens: “Passing the 50,000 units sold, especially when more than half of these sales were completed in the last 12 months is a tremendous achievement. More than a number of units sold, our team gets pride in supporting physicians to provide accurate diagnostic and proper treatment to their patients.”

Scroll to Top